newsfilter
← Latest News
GlobeNewswire·

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes,